European Organisation for Research and Treatment of Cancer

Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial

Background In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, n...

Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project

Despite advances in cancer treatment, the growing global cancer burden underscores the need for comprehensive and supportive care to address the needs of patients and their families. However, access to psycho-oncological support remains often limited across healthcare systems. Th...

The SISAQOL-IMI glossary: harmonising terminology for patient-reported outcomes in cancer clinical trials

Abstract Background This study presents the development of a glossary designed to harmonize terminology, foster consensus and support the successful implementation of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cance...